XNW27011

Phase 2

Astellas Pharma (ALPMY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ALPMYPhase 2$27.2B

XNW27011 Phase 2 Est. Readout

XNW27011• Pancreatic Adenocarcinoma Metastatic240

Dec 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Pancreatic Adenocarcinoma Metastatic

View Full Landscape

Drug Information

Target Indication

Pancreatic Adenocarcinoma Metastatic

Clinical Trial

NCT06792435

Last updated: 8/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

Vernakalant Injection 20 mg/mLPhase 3

Atrial Flutter

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts